- Home
- LVTX vs IGC Comparison
LVTX vs IGC Comparison
Compare LVTX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- IGC
- Stock Information
- Founded
- LVTX 2016
- IGC 2005
- Country
- LVTX Netherlands
- IGC United States
- Employees
- LVTX N/A
- IGC N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- IGC Health Care
- Exchange
- LVTX Nasdaq
- IGC Nasdaq
- Market Cap
- LVTX 40.8M
- IGC 39.8M
- IPO Year
- LVTX 2021
- IGC N/A
- Fundamental
- Price
- LVTX $1.58
- IGC $0.42
- Analyst Decision
- LVTX Hold
- IGC Strong Buy
- Analyst Count
- LVTX 4
- IGC 2
- Target Price
- LVTX $1.58
- IGC $4.00
- AVG Volume (30 Days)
- LVTX 437.0K
- IGC 695.2K
- Earning Date
- LVTX 08-13-2025
- IGC 11-11-2025
- Dividend Yield
- LVTX N/A
- IGC N/A
- EPS Growth
- LVTX N/A
- IGC N/A
- EPS
- LVTX N/A
- IGC N/A
- Revenue
- LVTX $4,990,000.00
- IGC $1,327,000.00
- Revenue This Year
- LVTX N/A
- IGC $15.26
- Revenue Next Year
- LVTX N/A
- IGC $3.41
- P/E Ratio
- LVTX N/A
- IGC N/A
- Revenue Growth
- LVTX N/A
- IGC 24.95
- 52 Week Low
- LVTX $0.85
- IGC $0.25
- 52 Week High
- LVTX $2.09
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- LVTX 59.32
- IGC 52.73
- Support Level
- LVTX $1.53
- IGC $0.39
- Resistance Level
- LVTX $1.64
- IGC $0.43
- Average True Range (ATR)
- LVTX 0.04
- IGC 0.02
- MACD
- LVTX 0.00
- IGC -0.00
- Stochastic Oscillator
- LVTX 87.12
- IGC 44.42
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.